TY - JOUR
T1 - Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males
AU - Van Esch, Hilde
AU - Bauters, Marijke
AU - Ignatius, Jaakko
AU - Jansen, Mieke
AU - Raynaud, Martine
AU - Hollanders, Karen
AU - Lugtenberg, Dorien
AU - Bienvenu, Thierry
AU - Jensen, Lars Riff
AU - Gécz, Jozef
AU - Moraine, Claude
AU - Marynen, Peter
AU - Fryns, Jean Pierre
AU - Froyen, Guy
N1 - Funding Information:
We are grateful to the patients and their families, for their cooperation. We thank Mrs. R. Mattlar, Dr. P. Hannikainen, Dr. A. Paetau, and Dr. H. von Koskull, for their help with obtaining blood and tissue samples from family L36, and Dr. C. Goizet, for the information on family T88. H.V.E. is a postdoctoral researcher of the Fund for Scientific Research–Flanders, Belgium (FWO-Vlaanderen). This work was supported by research grant G-0229-01 from FWO-Vlaanderen and by European Union RTD Project QLRT-2001-01810.
PY - 2005/9
Y1 - 2005/9
N2 - Loss-of-function mutations of the MECP2 gene at Xq28 are associated with Rett syndrome in females and with syndromic and nonsyndromic forms of mental retardation (MR) in males. By array comparative genomic hybridization (array-CGH), we identified a small duplication at Xq28 in a large family with a severe form of MR associated with progressive spasticity. Screening by real-time quantitation of 17 additional patients with MR who have similar phenotypes revealed three more duplications. The duplications in the four patients vary in size from 0.4 to 0.8 Mb and harbor several genes, which, for each duplication, include the MR-related L1CAM and MECP2 genes. The proximal breakpoints are located within a 250-kb region centromeric of L1CAM, whereas the distal breakpoints are located in a 300-kb interval telomeric of MECP2. The precise size and location of each duplication is different in the four patients. The duplications segregate with the disease in the families, and asymptomatic carrier females show complete skewing of X inactivation. Comparison of the clinical features in these patients and in a previously reported patient enables refinement of the genotype-phenotype correlation and strongly suggests that increased dosage of MECP2 results in the MR phenotype. Our findings demonstrate that, in humans, not only impaired or abolished gene function but also increased MeCP2 dosage causes a distinct phenotype. Moreover, duplication of the MECP2 region occurs frequently in male patients with a severe form of MR, which justifies quantitative screening of MECP2 in this group of patients.
AB - Loss-of-function mutations of the MECP2 gene at Xq28 are associated with Rett syndrome in females and with syndromic and nonsyndromic forms of mental retardation (MR) in males. By array comparative genomic hybridization (array-CGH), we identified a small duplication at Xq28 in a large family with a severe form of MR associated with progressive spasticity. Screening by real-time quantitation of 17 additional patients with MR who have similar phenotypes revealed three more duplications. The duplications in the four patients vary in size from 0.4 to 0.8 Mb and harbor several genes, which, for each duplication, include the MR-related L1CAM and MECP2 genes. The proximal breakpoints are located within a 250-kb region centromeric of L1CAM, whereas the distal breakpoints are located in a 300-kb interval telomeric of MECP2. The precise size and location of each duplication is different in the four patients. The duplications segregate with the disease in the families, and asymptomatic carrier females show complete skewing of X inactivation. Comparison of the clinical features in these patients and in a previously reported patient enables refinement of the genotype-phenotype correlation and strongly suggests that increased dosage of MECP2 results in the MR phenotype. Our findings demonstrate that, in humans, not only impaired or abolished gene function but also increased MeCP2 dosage causes a distinct phenotype. Moreover, duplication of the MECP2 region occurs frequently in male patients with a severe form of MR, which justifies quantitative screening of MECP2 in this group of patients.
UR - http://www.scopus.com/inward/record.url?scp=23944503759&partnerID=8YFLogxK
U2 - 10.1086/444549
DO - 10.1086/444549
M3 - Article
C2 - 16080119
AN - SCOPUS:23944503759
SN - 0002-9297
VL - 77
SP - 442
EP - 453
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 3
ER -